Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31428467 | 1.00 | PTGDR2 (0.72) | PTGDR2ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL2558715 | 0.84 | ALDH1A1 (0.67) | PTGDR2ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL354835 | 0.84 | PTGDR2 (1.00) | PTGDR2ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL14455032 | 0.83 | ALDH1A1 (0.52) | PTGDR2ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL5362778 | 0.82 | HTT (0.71) | ALDH1A1HTTSMN1; SMN2KDM4ELMNA | |
| SCHEMBL2561022 | 0.82 | PTGDR2 (0.62) | PTGDR2ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL9695894 | 0.82 | PTGDR2 (0.72) | PTGDR2ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL1287954 | 0.82 | PTGDR2 (0.72) | PTGDR2ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL2663792 | 0.80 | GCGR (0.50) | PTGDR2ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL9979665 | 0.80 | PTGDR2 (0.69) | PTGDR2ALDH1A1HTTSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200291027-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3539962-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2970330-B1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20180298003-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| US-10035800-B2 | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | ABBVIE INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20080306127-A9 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| WO-2008060569-A1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20070161690-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1713799-A2 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM, LLC (BM) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005077124-A2 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2005-08-25 | — | — | WO | disclosed |
| EP-1432686-B1 | TETRAHYDROISOCHINOLINES, THEIR PRODUCTION AND THE USE THEREOF AS ANALGESICS | BAYER HEALTHCARE AG (DE) | 2005-06-29 | — | — | EP | disclosed |
| US-20050049240-A1 | Tetrahydroisochinolines, their production and the use thereof as analgesics | BAYER HEALTHCARE AG (DE) | 2005-03-03 | — | — | US | disclosed |
| EP-1432686-A1 | TETRAHYDROISOCHINOLINES, THEIR PRODUCTION AND THE USE THEREOF AS ANALGESICS | Bayer HealthCare AG (DE) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003029221-A1 | TETRAHYDROISOCHINOLINES, THEIR PRODUCTION AND THE USE THEREOF AS ANALGESICS | BAYER HEALTHCARE AG (DE) | 2003-04-10 | — | — | WO | disclosed |
| US-5017586-A | 5-dialkylaminomethyl-2-furanomethanol derivatives having anti-hypertensive properties | GEROT-PHARMAZEUTIKA GESELLSCHAFT M.B.H. (AT) | 1991-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035800-B2 | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | BRD1, BRD3, BRD4 | PTGDR2 201/4885ALDH1A1 332/4885HTT 3655/4885 |
| US-20180298003-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | PTGDR2 402/4885ALDH1A1 2163/4885HTT 1423/4885 |
| US-20200291027-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | PTGDR2 402/4885ALDH1A1 2163/4885HTT 1423/4885 |
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | PTGDR2 402/4885ALDH1A1 2163/4885HTT 1423/4885 |
| US-20080306127-A9 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | BCL3, BCL2, BCLAF1 | PTGDR2 2835/4885ALDH1A1 3755/4885HTT 1713/4885 |
| US-20050049240-A1 | Tetrahydroisochinolines, their production and the use thereof as analgesics | OPRL1, OPRK1, TPMT | PTGDR2 193/4885ALDH1A1 1251/4885HTT 8/4885 |
| US-20070161690-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | BCL3, BCL2, BCLAF1 | PTGDR2 2835/4885ALDH1A1 3755/4885HTT 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.